Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date

Levin, Pavel A.; Dowell, Jonathan E.

doi:10.2147/ott.s113598

Cited by 17 publications

(10 citation statements)

References 41 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, researches to improve the malignant mesothelioma therapy have been actively attempt. The combinations of carboplatin and pemetrexed, or gemcitabine and cisplatin showed comparable outcomes with pemetrexed and cisplatin combination in phase- II trials [ 41 – 43 ]. The French Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS) demonstrated a statistically significant improvement in the median overall survival time using a combination of cisplatin, pemetrexed and bevacizumab, a monoclonal antibody that binds VEGF and blocks its interaction with the VEGF receptor [ 44 ].…”

Section: Discussionmentioning

confidence: 99%

“…The French Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS) demonstrated a statistically significant improvement in the median overall survival time using a combination of cisplatin, pemetrexed and bevacizumab, a monoclonal antibody that binds VEGF and blocks its interaction with the VEGF receptor [ 44 ]. In addition, several other molecular targeting and immunotherapeutic agents, such as anti-EGFR signaling agent and anti-programmed cell death 1 (PD-1) antibodies, are currently being investigated in clinical trials [ 43 ]. In this study, cSBL was demonstrated to induce apoptosis and inhibit tumor cell growth in xenografted mice.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Sialic acid-binding lectin from bullfrog eggs inhibits human malignant mesothelioma cell growth in vitro and in vivo

et al. 2018

View full text Add to dashboard Cite

Malignant mesothelioma is an aggressive cancer that results from exposure to asbestos. The therapeutic options for this type of cancer are limited; therefore, the development of novel therapeutic agents is urgently required. Sialic acid-binding lectin isolated from Rana catesbeiana oocytes (cSBL) is a novel therapeutic candidate for cancer, which exhibits antitumor activity mediated through RNA degradation. In the present study, we evaluated the effect of cSBL in vitro and in vivo. Xenograft-competent H2452 and MSTO human mesothelioma cell lines were treated with cSBL, and the pathway by which cSBL induces apoptosis was analyzed. In vivo studies were performed using nude mice inoculated with one of the two cell lines, and the effects of cSBL and pemetrexed were monitored simultaneously. Furthermore, the pharmacological interactions between the three agents (pemetrexed, cisplatin and cSBL) were statistically assessed. It was demonstrated that cSBL treatments caused morphological and biochemical apoptotic changes in both cell lines. Caspase cascade analysis revealed that an intrinsic pathway mediated cSBL-induced apoptosis. The administration of cSBL significantly inhibited tumor growth in two xenograft models, without any adverse effects. Furthermore, the combination index and dose reduction index values indicated that the cSBL + pemetrexed combination showed the highest synergism, and thus potential for reducing dosage of each drug, compared with the other combinations, including the existing pemetrexed + cisplatin regimen. cSBL exerted prominent antitumor effects on malignant mesothelioma cells in vitro and in vivo, and showed favorable effects when combined with pemetrexed. These results suggest that cSBL has potential as a novel drug for the treatment of malignant mesothelioma.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Sialic acid-binding lectin from bullfrog eggs inhibits human malignant mesothelioma cell growth in vitro and in vivo

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Surgery is not considered sufficient without adjuvant therapy, and thus, several chemotherapy programs are applied, including cisplatin, the antimetabolites pemetrexed or raltitrexed, gemcitabine, vinorelbine and, optionally, a combination with antiangiogenic agents like bevacizumab. 18 , 105 …”

Section: Discussion and Future Perspectivesmentioning

confidence: 99%

Amatuximab and novel agents targeting mesothelin for solid tumors

Baldo

Cecco

2017

OTT

View full text Add to dashboard Cite

Mesothelin (MSLN) is considered a promising target for cancer therapy. Originally extracted in 1992 after the immunization of mice with a human ovarian cancer (OC) cell line and cloned in 1996, MSLN seems to be involved in cell adhesion and metastasis. MSLN is prevalent in mesothelia tissues but is expressed in several human cancers, such as OC, pancreatic cancer, mesothelioma, and lung cancer. Amatuximab (MORAb-009) is a mouse-human chimeric monoclonal antibody with a selective affinity for MSLN. The principal mechanism of action comprises inhibition of binding of MSLN with the antigen CA125/MUC16. The highest phase of development is actually a Phase II trial (MORAb-009-201, Europe). In this review, we describe the mechanism of action of amatuximab and other MSLN-targeting novel drugs, along with a discussion about the expected efficacy, safety, and toxicity of this promising group of agents and implications for future research and clinical practice.

show abstract

“…Although platinum-pemetrexed are active agents in the first line treatment, only a minority of patients has clinical benefit. VEGF signaling is an important concept in mesothelioma cell pathophysiology (41). The addition of anti-angiogenesis agents to chemotherapy has been tested in several clinical studies.…”

Section: Addition Of Angiogenesis Inhibitorsmentioning

confidence: 99%

Current chemotherapy strategies in malignant pleural mesothelioma

Gooijer¹,

Baas²,

Burgers³

2018

Transl. Lung Cancer Res

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is an aggressive malignancy with a 5-year survival rate of ~10%. Since most patients present with irresectable disease, the vast majority is treated with chemotherapy. The only registered therapy for MPM is platinum-pemetrexed doublet therapy, although only up to half of patients have clinical benefit from this palliative treatment. Of the anti-angiogenesis agents, only bevacizumab and nintedanib have shown activity with platinum-pemetrexed doublet therapy. Other anti-angiogenesis agents like thalidomide did not prolong (progression free) survival or response rate. Eventually, all patients will get a recurrence and no active second line therapy has been identified to date. The clinical benefit of (switch) maintenance therapy after first line treatment and combination strategies of different chemotherapies with angiogenesis inhibitors are currently under investigation. The major challenges are finding optimal treatment combinations and to select the adequate treatment for an individual patient. This review focusses on the current standard of chemotherapy and new systemic therapy strategies under investigation.

show abstract

Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date

Cited by 17 publications

References 41 publications

Sialic acid-binding lectin from bullfrog eggs inhibits human malignant mesothelioma cell growth in vitro and in vivo

Sialic acid-binding lectin from bullfrog eggs inhibits human malignant mesothelioma cell growth in vitro and in vivo

Amatuximab and novel agents targeting mesothelin for solid tumors

Current chemotherapy strategies in malignant pleural mesothelioma

Contact Info

Product

Resources

About